San Francisco, 29 May 2024: The Report gRNA Market Size, Share & Trends Analysis Report By Product & Services (Products, Custom gRNA Synthesis Services), By gRNA Type (Research-Use), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030

The global gRNA market size is anticipated to reach USD 1.62 billion by 2030 and it is projected to grow at a CAGR of 18.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising adoption of Next-Generation Sequencing (NGS) is significantly boosting the market. As NGS technologies become more prevalent, they empower researchers and scientists with advanced capabilities for genomic analysis and manipulation. NGS enables high-throughput sequencing of genetic material, allowing for the rapid and cost-effective examination of entire genomes. This efficiency is crucial for gRNA applications, as it facilitates the identification and validation of target genes for genetic manipulation. NGS technologies provide a precise and comprehensive understanding of genomic sequences. This precision is vital for designing gRNAs with high specificity, ensuring accurate targeting of genes during the gene editing process using CRISPR/Cas systems.

Furthermore, the increasing investments by biotechnology and pharmaceutical companies for R&D activities are expected to fuel the market in the coming years. The development of user-friendly and affordable gRNA synthesis kits and services has made CRISPR-Cas9 technology more accessible to researchers of all levels. The continuous discovery of novel applications for CRISPR-Cas9 fuels the demand for gRNA.

Additionally, the launch of new gRNA final products can drive innovation, expand the market reach of players, and accelerate the adoption of gene editing technologies, contributing to the overall growth & advancement of the market. For instance, in October 2023, Synthego, a prominent provider of genome engineering solutions, launched IND-enabling (INDe) gRNAs. This transformative offering marks a significant advancement in the CRISPR-based cell and gene therapy preclinical pipeline. By providing researchers with high-quality gRNAs meticulously designed for GLP-regulated preclinical and IND-enabling studies, this product incorporates comprehensive IND-compliant materials and documentation throughout its design and production. Thus, it will drive the market growth.

gRNA is in high demand due to its pivotal role in CRISPR-based genetic editing. Its unique ability to guide the CRISPR system to specific DNA sequences makes it an indispensable tool in precision gene editing. Researchers and scientists rely on gRNA to precisely target and modify genes, enabling groundbreaking advancements in medicine, agriculture, & biotechnology. Its versatility, accuracy, and efficiency have propelled its demand, promising potential cures for genetic disorders, innovative agricultural practices, and the study of fundamental biological processes. As the quest for targeted genetic modifications intensifies, gRNA remains a sought-after component driving genetic research.

Request sample report of GRNA Market@ https://www.grandviewresearch.com/industry-analysis/grna-market-report/request/rs1

gRNA technology has shown potential in both areas, leading to the development of rapid CRISPR-based COVID-19 tests and research into CRISPR-based antiviral therapies. The pandemic increased public awareness and interest in gene-editing technologies such as CRISPR-Cas9, leading to greater recognition of gRNA's potential and driving market awareness. COVID-19 highlighted the importance of personalized medicine, as individuals responded differently to the virus.

gRNA Market Report Highlights

• On the basis of product & services, the product segment accounted for the largest revenue share of 73.4% in 2023. These products offer high accuracy, efficiency, and specificity in gene editing, making them popular among researchers is one of the primary drivers driving market expansion
• On the basis of gRNA type, the research-use segment dominated the market share in 2023. A large number of research programs conducted across various research institutes demand research-grade gRNA is driving up demand for this segment
• On the basis of application, the genome engineering segment dominated the market share in 2023. This growth can be attributed to the increasing demand for advanced genetic tools for research and therapeutic purposes
• On the basis of end-use, the pharmaceutical & biotechnology companies segment dominated the market share in 2023. The adoption of gRNA in precision medicine by pharmaceutical and biotech companies fuels its market growth as it becomes integral to the development of personalized therapies
• North America dominated the global industry in 2023 with a revenue share of 52.6% owing to the presence of key market players in the region. The majority of the key companies in this region have been actively involved in R&D activities involving gRNA

The expanding R&D activities in proteomics and genomics are significant factors driving the market. R&D efforts in genomics aim to identify and validate potential therapeutic targets and understand the functions of genes. gRNAs play a crucial role in this process by enabling precise gene editing using CRISPR/Cas systems. Researchers use gRNAs to modify genes of interest and study their effects, facilitating the identification and validation of key targets. Proteomics and genomics R&D often involve large-scale studies to uncover the functions of genes and proteins. gRNAs are instrumental in functional genomics research, allowing researchers to knock out or modulate specific genes selectively. This capability aids in understanding gene function and unraveling complex biological pathways.

Governments and private organizations are investing heavily in proteomics and genomics research, leading to a surge in demand for gRNA technology. For instance, in April 2021, the U.S. government announced USD 1.7 billion in funding to support and expand genomic sequencing technologies.

gRNA Market Report Scope

Merck KGaA, Thermo Fisher Scientific, Inc., and Agilent Technologies Inc. are some of the dominant players operating in gRNA market.

• Thermo Fisher Scientific, Inc. has a global presence and operates from over 65 locations in North America, Europe, Asia Pacific and other regions.
• Agilent Technologies, Inc. is a global company headquartered in Santa Clara, California, that provides instruments, software, services, and consumables for laboratories.

Jena Bioscience GmbH, System Biosciences, LLC.Synbio Technologies and others are some of the emerging market players functioning in the market.

• System Biosciences Company intended to provide comprehensive research for the discovery, isolation, and characterization of exosomes.
• Synbio Technologies offerings include antibody services, synthetic biology solutions, DNA editing, DNA reading, DNA/RNA writing, and protein & peptide services.

Key gRNA Companies:

• Thermo Fisher Scientific Inc.
• Agilent Technologies Inc.
• System Biosciences, LLC.
• Jena Bioscience GmbH
• Merck KGaA
• GENEWIZ (Azenta Life Sciences)
• Takara Bio Inc.
• Synbio Technologies
• Horizon Discovery Ltd.
• Synthego